Viewing Study NCT04609150



Ignite Creation Date: 2024-05-06 @ 3:21 PM
Last Modification Date: 2024-10-26 @ 1:48 PM
Study NCT ID: NCT04609150
Status: UNKNOWN
Last Update Posted: 2020-11-06
First Post: 2020-10-07

Brief Title: Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Multiple Myeloma MYELOMEFRAGIQUANTI
Sponsor: Assistance Publique - Hôpitaux de Paris
Organization: Assistance Publique - Hôpitaux de Paris

Study Overview

Official Title: Assessment of Vertebral Fat Quantitative MRI as a Marker of Bone Fragility in Patients With Multiple Myeloma
Status: UNKNOWN
Status Verified Date: 2020-09
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: Multiple myeloma is a disease that causes increased bone fragility which is often revealed or complicated by vertebral fractures Invasion of bone marrow by tumor plasma cells leads to bone destruction and reduced fat fraction The main objective is to assess the correlation between vertebral bone marrow fat fraction and bone fragility represented by a severity score of vertebral fractures The secondary objective is to assess the correlation with clinical and biological prognostic factors and scores
Detailed Description: Patients treated with vertebroplasty will be included during the period of the study retrospectively or prospectively

Mains collected data are represented by

Bone marrow fat fraction determined by MRI
Severity score for vertebral fractures
Clinical prognostic factors
Biological prognostic factors
Clinico-biological scores Descriptive statistics and correlation analyses will be performed between the measured parameters

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None